Woodline Partners Reduces $55M in Cytokinetics, Incorporated ($CYTK)
Key Points
- Woodline Partners changed its Cytokinetics, Incorporated ($CYTK) stake by 39.31% last quarter, cutting to 1,000,428 shares worth $85.23 million.
- Wall Street's consensus rating on $CYTK is Strong Buy and an average price target of $109.90.
- $CYTK last traded around $85.19.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Woodline Partners reduced its position in Cytokinetics, Incorporated ($CYTK) by 39.31% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,000,428 shares of Cytokinetics, Incorporated after selling 648,000 shares during the quarter. Woodline Partners's holdings in Cytokinetics, Incorporated were worth $85.23 million as of its most recent filing.
Cytokinetics, Incorporated Stock Up 18.2%
Shares of Cytokinetics, Incorporated ($CYTK) traded around $85.19 on Saturday, up 18.2% for the day.
Cytokinetics, Incorporated Earnings
Analysts Set New Price Targets
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Get Cytokinetics, Incorporated alerts
New 13F filings, insider trades, and analyst moves on $CYTK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.